Cover Image
市場調查報告書

醫藥品主要企業系列:主要醫藥品受託製造廠商 (CMO) 前30大企業(2017-2027年)

Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027: North America, Europe, Japan, India, China, Other Leading Developed Market API Manufacturers, API Manufacturing, FDF Manufacturing

出版商 Visiongain Ltd 商品編碼 274875
出版日期 內容資訊 英文 311 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品主要企業系列:主要醫藥品受託製造廠商 (CMO) 前30大企業(2017-2027年) Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027: North America, Europe, Japan, India, China, Other Leading Developed Market API Manufacturers, API Manufacturing, FDF Manufacturing
出版日期: 2017年07月18日 內容資訊: 英文 311 Pages
簡介

本報告提供全球主要醫藥品受託製造廠商 (CMO) 30家公司的簡介,企業的受託生產服務、營運概要,近幾年的財務成果分析,發展趨勢的評估,SWOT分析,及收益預測等系統性資訊。

第1章 調查概要

第2章 簡介:醫藥品受託製造市場

  • 受託製造企業所提供的服務是?
  • 醫藥品受託製造市場
  • 醫藥品受託製造市場展望
  • 醫藥品受託製造市場促進要素、阻礙要素
  • 主要的受託製造企業

第3章 北美的主要的醫藥品受託製造廠商 (CMO)

  • Catalent Pharma Solutions:全球有數的CMO之一
  • Patheon:CMO前3名公司的一角
  • Baxter BioPharma Solutions
  • AbbVie Contract Manufacturing
  • Pfizer CentreSource

第4章 歐洲的主要的醫藥品受託製造廠商 (CMO)

  • Lonza
  • Evonik Degussa
  • Royal DSM
  • Boehringer Ingelheim Contract Manufacturing
  • Fareva
  • Aenova Group
  • Famar
  • Vetter Pharmaceutical
  • Almac Group
  • Delpharm
  • Siegfried
  • Corden Pharmaceutical
  • Recipharm
  • Aesica Pharmaceuticals

第5章 日本的主要醫藥品受託製造廠商 (CMO)

  • Nipro:日本有數的CMO
  • Daito株式會社

第6章 已發展的市場主要的API廠商

  • Teva API
  • Esteve Quimica
  • Euticals

第7章 中國的主要醫藥品受託製造企業

  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals
  • Shandong Xinhua Pharmaceutical

第8章 印度的主要的醫藥品受託製造企業

  • Aurobindo Pharma
  • Divis Laboratories
  • Dr. Reddy's Laboratories

第9章 結論

  • 對近幾年的CMO市場領導來說的促進成長要素為何?
  • 成長策略:主要CMO的展望
  • 生物醫藥品製造服務的高需求
  • 新技術的投資
  • API製造商展望

附錄

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0214

The global pharmaceutical contract manufacturing market was valued at $76.6bn in 2016 and is expected to grow at a CAGR of 6.6% in the first half of the forecast period. Between 2011 and 2016, the top 5 emerging market CMOs grew at a CAGR of 13.6%, whereas the leading developed market CMOs grew at a CAGR of 1.7% over the same period.

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 311-page report you will receive 184 tables and 111 figures - all unavailable elsewhere.

The 311-page report provides clear detailed insight into the pharmaceutical CMOs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Pharmaceutical Contract Manufacturing Market forecast from 2017-2027:
    • API Manufacturing
    • FDF Manufacturing
    • Other Services
  • This report profiles 30 leading CMOs in North America, Europe, Japan, China and India:
    • Catalent
    • Patheon
    • Baxter
    • AbbVie
    • Pfizer
    • Lonza
    • Evonik Degussa
    • Royal DSM
    • Boehringer Ingelheim
    • Fareva
    • Aenova
    • Famar
    • Vetter
    • Almac
    • Delpharm
    • Siegfried
    • Corden
    • Recipharm
    • Aesica
    • Nipro
    • Daito
    • Teva API
    • Esteve Quimica
    • Euticals
    • Zhejiang Hisun Pharmaceuticals
    • Zhejiang Huahai Pharmaceuticals
    • Shandong Xinhua Pharmaceuticals
    • Aurobindo Pharma
    • Divis Laboratories
    • Dr. Reddy's Laboratories
  • The content of each profile differs, depending on the organisation. In general, a profile gives the following information:
  • Overview of the company's contract manufacturing services and operations
  • Analysis of recent financial performance - annual revenue for CMO services, including some data on operating profit and margins
  • Assessment of developments - activities, acquisitions, production capacity, deals, new service offerings and collaborations
  • SWOT analysis - a firm's strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2016 onwards
  • Forecasting of pharmaceutical manufacturing revenue to 2027, as well as projected operating profit and margin for some companies.

Visiongain's study is intended for anyone requiring commercial analyses for the top 30 pharmaceutical CMOs market. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027: North America, Europe, Japan, India, China, Other Leading Developed Market API Manufacturers, API Manufacturing, FDF Manufacturing.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Leading Contract Manufacturing Organisations (CMOs) Overview
  • 1.2. Benefits of This Report
  • 1.3. How This Report Delivers Information
  • 1.4. Main Questions This Report Answers
  • 1.5. Who is This Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Some Related Reports
  • 1.9. About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing, 2017

  • 2.1. What Services Do Contract Manufacturers Offer?
    • 2.1.1. Why Do Firms Outsource Manufacturing?
    • 2.1.2. What Is Driving Demand for Contract Manufacturing Services?
  • 2.2. The Pharmaceutical Contract Manufacturing Market, 2016
    • 2.2.1. Where is Supply and Demand Highest for Contract Manufacturing Services?
  • 2.3. Outlook for the Pharmaceutical Contract Manufacturing Market 2017-2027
  • 2.4. Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2017-2027
    • 2.4.1. Pharmaceutical Contract Manufacturing: Market Drivers 2017-2027
    • 2.4.2. Pharmaceutical Contract Manufacturing: Market Restraints 2017-2027
  • 2.5. Who Are the Leading Pharmaceutical Contract Manufacturers in 2016?

3. Leading CMOs in North America

  • 3.1. Catalent Pharma Solutions- the World's Leading CMO
    • 3.1.1. Catalent: Manufacturing Services and Capabilities
    • 3.1.2. Divisional Segmentation - Breaking down Catalent's Service
    • 3.1.3. Catalent Pharma's Revenue Growth, 2011-2016
    • 3.1.4. Sustained Growth in Oral Products: Catalent Pharma's Divisional Performance, 2011-2016
    • 3.1.5. Catalent Is Expanding its Softgel Technologies Division
    • 3.1.6. Quadrupling Biopharmaceutical Manufacturing Capacity
    • 3.1.7. Expansion of Packaging Services in Asia-Pacific and Europe: 2015
    • 3.1.8. Adding New Early-Stage Development Services
    • 3.1.9. Expansion in Japan - Growth Prospects for Catalent
    • 3.1.10. New Business Contracts 2014-2016
    • 3.1.11. Catalent New Products Launch
    • 3.1.12. Catalent: Opportunities for Growth 2017-2027
    • 3.1.13. Catalent: Mild Growth in Revenue, 2017-2027
  • 3.2. Patheon - One of the Top 3 CMOs
    • 3.2.1. Patheon - Global leader in Pharmaceutical Development Services
    • 3.2.2. Contract Manufacturing Services at Patheon
    • 3.2.3. Steady Revenue Growth 2011-2016
    • 3.2.4. DPx Holdings: Developments
    • 3.2.5. Adding New Formulations and Formulation Development Services
    • 3.2.6. Expanding Services Through Acquisition, 2016
    • 3.2.7. Patheon: SWOT Analysis 2017-2027
    • 3.2.8. Patheon: Contract Manufacturing Revenue Forecast 2017-2027
  • 3.3. Baxter BioPharma Solutions
    • 3.3.1. Baxter BioPharma is the Global Leader in Sterile Fill and Finish
    • 3.3.2. Historic Revenue Performance 2011-2016
    • 3.3.3. Baxter BioPharma SWOT Analysis 2017-2027
    • 3.3.4. Baxter BioPharma Revenue Forecast 2017-2027
    • 3.3.5. Reassessing Manufacturing Capacity
  • 3.4. AbbVie Contract Manufacturing
    • 3.4.1. AbbVie Offers Full-Service Contract Manufacturing
    • 3.4.2. Expanding and Adding New Services: 2013-2014
    • 3.4.3. AbbVie Contract Manufacturing: Revenue 2011-2016
    • 3.4.4. Biologics and HPAPIs Are an Opportunity for Growth 2017-2027
    • 3.4.5. AbbVie Contract Manufacturing Revenue Forecast 2017-2027
  • 3.5. Pfizer CentreOne
    • 3.5.1. Pfizer CentreSource: Historic Revenue Performance, 2011-2016
    • 3.5.2. Will Hospira Acquisition Lead to Revenue Growth in Future?
    • 3.5.3. Outlook for CentreOne: Revenue Forecast 2017-2027

4. Leading European Contract Manufacturing Organisations

  • 4.1. Lonza
    • 4.1.1. Lonza Is a Leader in Biologics Manufacturing
    • 4.1.2. Lonza Contract Manufacturing and Development: 2011-2016
    • 4.1.3. Investing in Advanced Biological Drug Sectors
    • 4.1.4. The Promise of Antibody-Drug Conjugates (ADCs)
    • 4.1.5. The Regenerative Medicine Future in Japan
    • 4.1.6. Lonza: SWOT Analysis 2017-2027
    • 4.1.7. Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2017-2027
  • 4.2. Evonik Degussa
    • 4.2.1. Investing in API and Drug Delivery Services
    • 4.2.2. Moderate Growth in Pharmaceutical Manufacturing Services, 2011-2016
    • 4.2.3. Evonik Is a HPAPI Specialist
    • 4.2.4. Evonik Continues to Grow Across All Segments
    • 4.2.5. How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
    • 4.2.6. Evonik Degussa: Revenue Forecast 2017-2027
  • 4.3. Royal DSM
    • 4.3.1. Amplified Revenue Growth in Pharma Manufacturing 2011-2016
    • 4.3.2. DSM Pharmaceuticals Products/DPx Holdings: Manufacturing Services 2011-2016
    • 4.3.3. DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
    • 4.3.4. DPx Holdings: A New Pharma Leader
    • 4.3.5. Investing in Biopharma Manufacturing
    • 4.3.6. Expanding API Manufacturing
    • 4.3.7. Generics and Biologics Are an Opportunity for Growth, 2017-2027
    • 4.3.8. DSM Pharmaceuticals Products: Revenue Forecast 2017-2027
  • 4.4. Boehringer Ingelheim Contract Manufacturing
    • 4.4.1. Expanding Biopharmaceuticals Manufacturing Services in China
    • 4.4.2. Production Through to Fill and Finished Biopharmaceuticals
    • 4.4.3. A Track Record of Production for 29 Biopharma Products
    • 4.4.4. Increasing Revenue from Contract Manufacturing, 2011-2016
    • 4.4.5. Pulling Out of Small Molecule API Manufacturing
    • 4.4.6. Expanding through New Services
    • 4.4.7. Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2017-2027
    • 4.4.8. Boehringer Ingelheim: Revenue Forecast 2017-2027
  • 4.5. Fareva
    • 4.5.1. Fareva Has 35 Years' Manufacturing Experience
    • 4.5.2. Revenue Growth through Acquisitions: 2011-2016
    • 4.5.3. Fareva SWOT Analysis: 2017-2027
    • 4.5.4. Fareva Revenue Forecast: 2017-2027
  • 4.6. Aenova Group
    • 4.6.1. Acquisition of Haupt Creates European CMO Giant
    • 4.6.2. Aenova's Ever Expanding Manufacturing Capacity
    • 4.6.3. Aenova's Revenue 2011-2016: Organic Growth and Acquisitions
    • 4.6.4. Aenova's Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2016
    • 4.6.5. Becoming a Leading Contract Manufacturer: Aenova Revenue Forecast 2017-2027
  • 4.7. Famar
    • 4.7.1. Famar Is an Expert in Lyophilisation
    • 4.7.2. Sustained Growth in Famar's Revenue: 2011-2016
    • 4.7.3. Expanding Outside Europe
    • 4.7.4. Further Site Acquisitions Are an Opportunity for Growth 2017-2027
    • 4.7.5. How Will Famar Perform 2017-2027?
  • 4.8. Vetter Pharmaceutical
    • 4.8.1. Vetter is an Injectable Manufacturing Specialist
    • 4.8.2. Rapidly Growing Revenue in the US and Germany: 2011-2016
    • 4.8.3. Services, Collaborations and Differentiating Factors
    • 4.8.4. Expanding Services in US and Asia
    • 4.8.5. Biologics Are an Opportunity for Growth for Vetter 2017-2027
    • 4.8.6. Vetter Outlook: Revenue Forecast 2017-2027
  • 4.9. Almac Group
    • 4.9.1. Almac's Manufacturing Services
    • 4.9.2. Almac Outpaces the Market: 2011-2016
    • 4.9.3. Almac Adding Capacity Globally
    • 4.9.4. New Services Added 2012-2016
    • 4.9.5. Almac Group: Contract Manufacturing Market Outlook 2017-2027
    • 4.9.6. How Will Almac Group Perform 2017-2027?
  • 4.10. Delpharm
    • 4.10.1. Finished Dosage Form Manufacturing for Developed Markets
    • 4.10.2. Delpharm: Rapid Revenue Growth Via Acquisitions, 2011-2016
    • 4.10.3. Delpharm: Outlook and Prospects for Growth 2017-2027
    • 4.10.4. Generics Will Drive Revenue Growth for Delpharm 2017-2027
  • 4.11. Siegfried
    • 4.11.1. Siegfried's Acquisitions, 2011-2016
    • 4.11.2. Expanding Siegfried's Manufacturing Footprint Globally
    • 4.11.3. Expanding High Potency API Capabilities
    • 4.11.4. Siegfried: Financial Performance 2011-2016
    • 4.11.5. Siegfried's Characteristics within the Contract Manufacturing Market: SWOT Analysis 2016
    • 4.11.6. Continued Revenue Growth for Siegfried 2017-2027
  • 4.12. Corden Pharmaceutical
    • 4.12.1. CordenPharma Service Division
    • 4.12.2. CordenPharma Emerging in the API Market
    • 4.12.3. Investments in Highly Potent Capabilities
    • 4.12.4. CordenPharma: SWOT Analysis 2017-2027
  • 4.13. Recipharm
    • 4.13.1. Contract Development and Manufacturing Services
    • 4.13.2. Recipharm: Financial Performance 2011-2016
    • 4.13.3. Recipharm Invests in Facility Expansion
    • 4.13.4. Recipharm Growing in the Development and Technology Market Through Acquisitions
    • 4.13.5. Recipharm: Opportunities for Growth 2017-2027
    • 4.13.6. Outlook for Recipharm: Revenue Forecast 2017-2027
  • 4.14. Aesica Pharmaceuticals
    • 4.14.1. Aesica Manufactures APIs and Finished Dosage Forms
    • 4.14.2. Acquisitions Drive Revenue Growth but Operational Margins Have Declined, 2011-2016
    • 4.14.3. Partnering with Academia for Innovative Solutions
    • 4.14.4. Growth through Acquisitions and Internal Expansion
    • 4.14.5. Aesica: Opportunities for Expansion 2017-2027
    • 4.14.6. Forecast Aesica Financial Performance, 2017-2027

5. Leading Japanese Pharma Contract Manufacturing Organisations

  • 5.1. Nipro Corporation: Japan's Leading CMO
    • 5.1.1. Nipro Pharmaceutical Contract Manufacturing Capabilities
    • 5.1.2. Nipro: Decline in Revenue But increasing Operating Profits 2011-2016
    • 5.1.3. Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2017-2027
    • 5.1.4. Nipro Revenue and Profitability Forecast 2017-2027
  • 5.2. Daito Pharmaceutical
    • 5.2.1. Daito Has a Portfolio of More than 30 APIs
    • 5.2.2. Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2011-2016
    • 5.2.3. Daito Is Well-Placed for Asian Market Growth - SWOT Analysis 2017-2027
    • 5.2.4. Sustained Growth in Revenue and Operating Profit for Daito, 2017-2027

6. Leading Developed-Market API Specialists

  • 6.1. Teva API
    • 6.1.1. API Manufacturing Services
    • 6.1.2. Teva API: Financial Performance 2011-2016
    • 6.1.3. Building a Footprint in Mexico, India and China
    • 6.1.4. Teva API: SWOT Analysis 2017-2027
    • 6.1.5. Outlook for Teva API: Revenue Forecast 2017-2027
  • 6.2. Esteve Química
    • 6.2.1. Esteve Química Manufactures APIs for Developed and Emerging Markets
    • 6.2.2. Expanding in the US, 2016
    • 6.2.3. Esteve Química: SWOT Analysis 2017-2027
  • 6.3. Euticals
    • 6.3.1. Euticals Manufactures More than 200 APIs
    • 6.3.2. Acquisitions Drive Growth 2011-2016
    • 6.3.3. Adding Capacity for Finished Dosage Forms
    • 6.3.4. Asian Expansion Is an Opportunity for Growth 2017-2027
    • 6.3.5. Euticals: Revenue Forecast 2017-2027

7. Leading Chinese Pharma Contract Manufacturers

  • 7.1. Zhejiang Hisun Pharmaceutical
    • 7.1.1. API Manufacturing for Markets Worldwide
    • 7.1.2. Zhejiang Hisun's Rapid Growth in API Revenue Grows, 2011-2016
    • 7.1.3. Moving into International Drug Marketing
    • 7.1.4. Zhejiang Hisun: Opportunities for Growth 2017-2027
    • 7.1.5. Zhejiang Hisun: Strong API Revenue Growth 2017-2027
  • 7.2. Zhejiang Huahai Pharmaceuticals
    • 7.2.1. Zhejiang Huahai Is a Market Leader Within the Antihypertensive API Market
    • 7.2.2. Zhejiang Huahai: Contract Manufacturing Performance 2011-2016
    • 7.2.3. Expanding in the US Generic Drugs Market
    • 7.2.4. Zhejiang Huahai: SWOT Analysis, 2017-2027
    • 7.2.5. Zhejiang Huahai: Revenue Forecast, 2017-2027
  • 7.3. Shandong Xinhua Pharmaceutical
    • 7.3.1. Experience in APIs and Finished Dosage Forms
    • 7.3.2. Shandong Xinhua: Strong Revenue Growth 2011-2016
    • 7.3.3. Growing through Joint Ventures
    • 7.3.4. Looking to Expand in the US and EU 2017-2027
    • 7.3.5. Shandong Xinhua Pharmaceutical: Revenue Forecast 2017-2027

8. Leading Indian Pharmaceutical Contract Manufacturers

  • 8.1. Aurobindo Pharma
    • 8.1.1. API Manufacturing Services
    • 8.1.2. Aurobindo Pharma: Steady Revenue Growth 2011-2016
    • 8.1.3. Aurobindo Expanding Outside of Antibacterials
    • 8.1.4. Aurobindo: Opportunities for Expansion 2017-2027
    • 8.1.5. How Will Aurobindo's Contract Manufacturing Division Perform 2017-2027?
  • 8.2. Divis Laboratories
    • 8.2.1. Divis Laboratories and the Contract Manufacturing Industry
    • 8.2.2. Divis Laboratories: A Rapidly Growing CMO, 2011-2016
    • 8.2.3. Divis Laboratories: API Manufacturing Outlook 2017-2027
    • 8.2.4. Divis Laboratories: API Manufacturing Revenue Forecast, 2017-2027
  • 8.3. Dr. Reddy's Laboratories
    • 8.3.1. API and FDF Manufacturing Services
    • 8.3.2. Dr. Reddy's PSAI: Strong Revenue Growth 2011-2016
    • 8.3.3. Advancing in Complex Drug Manufacturing
    • 8.3.4. Expanding in the European Manufacturing Market
    • 8.3.5. Dr. Reddy's PSAI Division: Revenue Forecast 2017-2027

9. Conclusions of the Study

  • 9.1. What Has Driven Growth for CMO Market Leaders in Recent Years?
  • 9.2. Strategies for Growth: Prospects for Leading CMOs, 2017-2027
  • 9.3. High Demand for Biopharmaceutical Manufacturing Services
  • 9.4. Investing in Novel Technologies
  • 9.5. Outlook for API Manufacturers
  • Appendices
  • Some Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Table

  • Table 2.1: Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2017
  • Table 2.2: Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2014-2016
  • Table 2.3: Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), 2016
  • Table 2.4: Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2016
  • Table 2.5: Contract Manufacturing Market Forecast by Service: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2021 and 2027
  • Table 2.6: Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2016
  • Table 3.1: Catalent Details, 2016
  • Table 3.2: Catalent Facility Details, 2016
  • Table 3.3: Catalent Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2011-2016
  • Table 3.4: Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2016
  • Table 3.5: Catalent Financial Performance by Division: Revenue ($m), Annual Growth Rate (%), Revenue Share (%), CAGR (%), 2011-2016
  • Table 3.6: Catalent New Products Launch: New Products, Annual growth (%), CAGR (%), 2012-2016
  • Table 3.7: Catalent Pharma SWOT Analysis, 2017
  • Table 3.8: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 3.9: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2021-2027
  • Table 3.10: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 3.11: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 3.12: Patheon Details, 2016
  • Table 3.13: Patheon Manufacturing Facilities, 2017
  • Table 3.14: Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 3.15: Patheon: SWOT Analysis, 2016
  • Table 3.16: Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 3.17: Baxter BioPharma Solutions Details, 2016
  • Table 3.18: Baxter BioPharma Solutions: Facilities and Services Offered, 2016
  • Table 3.19: Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 3.20: Baxter BioPharma Solutions SWOT Analysis, 2016
  • Table 3.21: Forecast Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 3.22: AbbVie Contract Manufacturing: Details, 2016
  • Table 3.23: AbbVie Contract Manufacturing Facility Capabilities, 2016
  • Table 3.24: AbbVie Pharmaceutical Manufacturing: Revenue ($m) Annual Growth Rate (%), 2011-2016
  • Table 3.25: AbbVie Contract Manufacturing SWOT Analysis, 2016
  • Table 3.26: Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 3.27: Pfizer CentreOne Details, 2016
  • Table 3.28: Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 3.29: Pfizer CentreOne SWOT Analysis, 2016
  • Table 3.30: Forecast Pfizer CentreOne Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 4.1: Lonza Details, 2016
  • Table 4.2: Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
  • Table 4.3: Lonza Pharma & Biotech Department: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2011-2016
  • Table 4.4: ADCs Approved and in Late Stage Clinical Development, 2014
  • Table 4.5: Lonza SWOT Analysis, 2016
  • Table 4.6: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2016-2021
  • Table 4.7: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2022-2027
  • Table 4.8: Evonik Degussa Details, 2016
  • Table 4.9: Evonik Health and Nutrition: R&D and Production Sites by Region, 2016
  • Table 4.10: Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 4.11: Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2016
  • Table 4.12: Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.13: Royal DSM Details, 2016
  • Table 4.14: Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%) 2011-2016
  • Table 4.15: DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 4.16: DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 4.17: DSM Pharmaceutical Manufacturing: SWOT Analysis, 2016
  • Table 4.18: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 4.19: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2022-2027
  • Table 4.20: Boehringer Ingelheim Biopharmaceuticals Details, 2016
  • Table 4.21: Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2014
  • Table 4.22: Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
  • Table 4.23: Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 4.24: Boehringer Ingelheim: SWOT Analysis, 2016
  • Table 4.25: Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.26: Fareva Details, 2016
  • Table 4.27: Fareva Manufacturing Facilities, 2016
  • Table 4.28: Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.29: Fareva: SWOT Analysis, 2016
  • Table 4.30: Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.31: Aenova Group Details, 2016
  • Table 4.32: Aenova Group Manufacturing Capacity by Dosage Form, 2016
  • Table 4.33: Aenova Group Manufacturing Facility Details, 2016
  • Table 4.34: Aenova Group Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2011-2016
  • Table 4.35: Aenova Group SWOT Analysis, 2016
  • Table 4.36: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2016-2021
  • Table 4.37: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2022-2027
  • Table 4.38: Famar Details, 2016
  • Table 4.39: Famar Pharmaceutical Manufacturing Facilities, 2016
  • Table 4.40: Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.41: Famar: SWOT Analysis, 2016
  • Table 4.42: Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.43: Vetter Details, 2016
  • Table 4.44: Vetter Pharmaceutical Facilities, 2016
  • Table 4.45: Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.46: Vetter: SWOT Analysis, 2016
  • Table 4.47: Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.48: Almac Details, 2016
  • Table 4.49: Almac Pharmaceutical Manufacturing Facilities Details, 2016
  • Table 4.50: Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.51: Almac: SWOT Analysis, 2016
  • Table 4.52: Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2016-2021
  • Table 4.53: Forecast Almac Pharmaceuticals: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), 2022-2027
  • Table 4.54: Delpharm Details, 2016
  • Table 4.55: Delpharm: Facilities and Services, 2016
  • Table 4.56: Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.57: Delpharm: SWOT Analysis, 2016
  • Table 4.58: Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.59: Siegfried Details, 2016
  • Table 4.60: Siegfried Pharmaceutical Manufacturing Facilities Details, 2016
  • Table 4.61: Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.62: Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.63: Siegfried: SWOT Analysis, 2016
  • Table 4.64: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2016-2021
  • Table 4.65: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2022-2027
  • Table 4.66: CordenPharma Details, 2016
  • Table 4.67: CordenPharma Facilities and Service Details, 2016
  • Table 4.68: Corden Pharmaceuticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.69: Corden Pharmaceuticals SWOT Analysis, 2016
  • Table 4.70: Recipharm Details, 2016
  • Table 4.71: Recipharm: Facility Details and Services, 2016
  • Table 4.72: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.73: Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2016
  • Table 4.74: Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2016
  • Table 4.75: Recipharm: SWOT Analysis, 2016
  • Table 4.76: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2016-2021
  • Table 4.77: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2022-2027
  • Table 4.78: Aesica Details, 2016
  • Table 4.79: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.80: Aesica SWOT Analysis, 2016
  • Table 4.81: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2016-2021
  • Table 4.82: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2022-2027
  • Table 5.1: Nipro Pharma Details, 2016
  • Table 5.2: Nipro Pharmaceutical Contract Manufacturing Capabilities: 2011-2016
  • Table 5.3: Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2016
  • Table 5.4: Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2011-2016
  • Table 5.5: Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2016
  • Table 5.6: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 5.7: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 5.8: Daito Pharmaceuticals: Details, 2016
  • Table 5.9: Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2011-2016
  • Table 5.10: Daito Pharmaceuticals SWOT Analysis, 2016
  • Table 5.11: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 5.12: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 6.1: Teva API Details, 2016
  • Table 6.2: Teva API: Site Acquisitions, 1980- 2011
  • Table 6.3: Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 6.4: Teva API SWOT Analysis, 2016
  • Table 6.5: Forecast Teva API Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 6.6: Esteve Química Details, 2016
  • Table 6.7: Esteve Química SWOT Analysis, 2016
  • Table 6.8: Euticals Details, 2016
  • Table 6.9: Euticals Facility Details: Production Capacity (m3) and Key Products, 2016
  • Table 6.10: Euticals Cumulative Regulatory Filings by Region/Country: Filings, Share of Total (%), 2016
  • Table 6.11: Euticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 6.12: Euticals Revenue by Product Class: Revenue ($m), Share of Total (%), 2016
  • Table 6.13: Euticals Revenue by Region: Revenue ($m), Share of Total (%), 2016
  • Table 6.14: Euticals SWOT Analysis, 2016
  • Table 6.15: Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 7.1: Zhejiang Hisun Pharmaceuticals Details, 2016
  • Table 7.2: Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 7.3: Zhejiang Hisun Manufacturing: SWOT Analysis, 2016
  • Table 7.4: Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 7.5: Zhejiang Huahai Pharmaceuticals Details, 2016
  • Table 7.6: Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 7.7: Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2016
  • Table 7.8: Forecast Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 7.9: Shandong Xinhua Pharmaceuticals Details, 2016
  • Table 7.10: Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2016
  • Table 7.11: Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 7.12: Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2016
  • Table 7.13: Shandong Xinhua Manufacturing: SWOT Analysis, 2016
  • Table 7.14: Forecast Shandong Xinhua Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 8.1: Aurobindo Pharma Details, 2016
  • Table 8.2: Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 8.3: Aurobindo Contract Manufacturing Revenue by API Class: Revenue ($m), Revenue Share (%), 2014
  • Table 8.4: Aurobindo Contract Manufacturing: SWOT Analysis, 2016
  • Table 8.5: Forecast Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 8.6: Divis Laboratories Details, 2016
  • Table 8.7: Divis Laboratories: Facility Details, Production Capacity and Services, 2016
  • Table 8.8: Divis Laboratories: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 8.9: Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2016
  • Table 8.10: Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2016
  • Table 8.11: Divis Laboratories Contract Manufacturing: SWOT Analysis, 2016
  • Table 8.12: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 8.13: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 8.14: Dr. Reddy's Laboratories Details, 2016
  • Table 8.15: Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 1987-2014
  • Table 8.16: Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 8.17: Dr. Reddy's Laboratories Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), FY 2016
  • Table 8.18: Dr. Reddy's Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2016
  • Table 8.19: Dr. Reddy's Laboratories: SWOT Analysis, 2016
  • Table 8.20: Forecast Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 9.1: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 9.2: CMOs by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2011-2016
  • Table 9.3: Leading CMOs: Combined Annual Revenue ($m), Annual Growth (%), Market Share (%), CAGR (%), 2016-2027
  • Table 9.5: CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2015-2020
  • Table 9.6: CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2021-2027

List of Figures

  • Figure 1.1: Segmentation of Contract Manufacturing Organisations, 2017
  • Figure 2.1: Selected Services Contracted to CMOs by Developmental Stage, 2017
  • Figure 2.2: Contract Manufacturing Market Total Revenue: Total Revenue ($bn), 2014-2016
  • Figure 2.3: Contract Manufacturing Market by Service: Market Share (%), 2016
  • Figure 2.4: Contract Manufacturing Market by Leading Country: Market Share (%), 2016
  • Figure 2.5: Contract Manufacturing Market Forecast by Service: Market Size ($bn), 2016, 2021 and 2027
  • Figure 2.6: Pharmaceutical Contract Manufacturing: Drivers and Restraints, 2017-2027
  • Figure 3.1: Catalent Facilities by Region, 2016
  • Figure 3.2: Catalent Facilities by Service Offered, 2016
  • Figure 3.3: Catalent Financial Performance: Revenue ($m), 2011-2016
  • Figure 3.4: Catalent Financial Performance by Product Type: Revenue Share (%), 2016
  • Figure 3.5: Catalent Financial Performance by Division: Revenue ($m), 2011-2016
  • Figure 3.6: Catalent New Products Launch: New products, 2012-2016
  • Figure 3.7: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
  • Figure 3.8: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2022-2027
  • Figure 3.9: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), 2016-2027
  • Figure 3.10: Patheon Pharmaceutical Development Projects (%) by Phase, 2016
  • Figure 3.11: Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2016
  • Figure 3.12: Patheon Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 3.13: Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 3.14: Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2016-2027
  • Figure 3.15: Baxter BioPharma Manufacturing: Revenue ($m), 2011-2016
  • Figure 3.16: Forecast Baxter BioPharma Manufacturing: Revenue ($m), 2016-2027
  • Figure 3.17: AbbVie Pharmaceutical Manufacturing: Revenue ($m)*, 2011-2016
  • Figure 3.18: Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 3.19: Pfizer CentreOne: Revenue ($m), 2011-2016
  • Figure 3.20: Forecast Pfizer CentreOne Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.1: Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
  • Figure 4.2: Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2016
  • Figure 4.3: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 4.4: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 4.5: Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2016
  • Figure 4.6: Evonik Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.7: Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.8: Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.9: DSM Pharmaceutical Products (DPP)/ DPx Holdings Division: Revenue ($m), 2011-2016
  • Figure 4.10: DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2011-2016
  • Figure 4.11: Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2016-2027
  • Figure 4.12: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.13: Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.14: Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.15: Fareva Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.16: Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.17: Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.18: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
  • Figure 4.19: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2022-2027
  • Figure 4.20: Famar Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.21: Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.22: Vetter Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.23: Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.24: Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.25: Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
  • Figure 4.26: Forecast Almac Pharmaceuticals: Revenue ($m), 2022-2027
  • Figure 4.27: Delpharm: Revenue ($m), 2011-2016
  • Figure 4.28: Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.29: Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
  • Figure 4.30: Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), 2011-2016
  • Figure 4.31: Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2015
  • Figure 4.32: Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2016
  • Figure 4.33: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 4.34: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 4.35: Corden Pharmaceuticals: Revenue ($m), 2011-2016
  • Figure 4.36: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
  • Figure 4.37: Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2016
  • Figure 4.38: Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2016
  • Figure 4.39: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 4.40: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 4.41: Aesica Pharmaceuticals: Revenue ($m)*, Operating Profit ($m)*, Operating Margin (%), 2011-2016
  • Figure 4.42: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 4.43: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 5.1: Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2011-2016
  • Figure 5.2: Nipro Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
  • Figure 5.3: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 5.4: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 5.5: Daito Pharmaceuticals Financial Performance: Revenue (¥m), Operating Profit (¥m), Operating Margin (%), 2011-2016
  • Figure 5.6: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 5.7: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 6.1: Teva API: Revenue ($m), 2011-2016
  • Figure 6.2: Forecast Teva API Manufacturing: Revenue ($m), 2016-2027
  • Figure 6.3: Euticals Cumulative Regulatory Filings by Region/Country: Share of Total (%), 2016
  • Figure 6.4: Euticals: Revenue ($m), 2011-2016
  • Figure 6.5: Euticals Revenue by Product Class: Share of Total Revenues (%), 2016
  • Figure 6.6: Euticals Revenue by Region: Share of Total Revenues (%), 2016
  • Figure 6.7: Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 7.1: Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2011-2016
  • Figure 7.2: Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2016-2027
  • Figure 7.3: Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2011-2016
  • Figure 7.4: Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2016-2027
  • Figure 7.5: Shandong Xinhua: Revenue ($m), 2011-2016
  • Figure 7.6: Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2016
  • Figure 7.7: Forecast Shandong Xinhua Manufacturing: Revenue ($m), 2016-2027
  • Figure 8.1: Aurobindo Contract Manufacturing: Revenue ($m), 2011-2016
  • Figure 8.2: Aurobindo Contract Manufacturing: Revenue Share (%), 2014
  • Figure 8.3: Forecast Aurobindo Contract Manufacturing: Revenue ($m), 2016-2027
  • Figure 8.4: Divis Laboratories Contract Manufacturing: Revenue ($m), EBTDA ($m), EBITDA Margin (%), 2011-2016
  • Figure 8.5: Divis Laboratories Revenue Distribution: Revenue ($m), 2016
  • Figure 8.6: Divis Laboratories Revenue by Region: Share of Total (%), 2016
  • Figure 8.7: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2016-2021
  • Figure 8.8: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2022-2027
  • Figure 8.9: Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 1987-2016
  • Figure 8.10: Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), 2011-2016
  • Figure 8.11: Dr. Reddy's Laboratories Drug Master File (DMF) Applications: Accepted Applications by Region (%), FY 2015
  • Figure 8.12: Dr. Reddy's Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2016
  • Figure 8.13: Forecast Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), 2016-2027
  • Figure 9.1: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2011-2016
  • Figure 9.2: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2011-2016
  • Figure 9.3: Leading CMOs: Combined Annual Revenue ($bn), 2016-2027
  • Table 9.4: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Figure 9.4: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2016-2027
  • Figure 9.5: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2015-2020
  • Figure 9.6: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2021-2027

Companies Listed

  • Abbott Laboratories
  • Abic
  • AbbVie
  • Actavis
  • Adamas Pharmaceuticals
  • Aegerion
  • Aenova Group
  • Aesica Pharmaceuticals
  • Agennix
  • Aguettant
  • AlgoNomics
  • Alliance Medical Products
  • Almac Group
  • Alpharma
  • Amgen
  • AMYRA Biotech
  • Andeno
  • Apexigen
  • Aptuit
  • Archimica
  • Arecor
  • ArGEN-X
  • Astellas
  • AstraZeneca
  • Athera Biotechnologies
  • Aurobindo Pharma
  • Avalanche Biotechnologies
  • Banner Life Sciences
  • BaroFold
  • Barr-Pliva
  • BASF
  • Baxter BioPharma Solutions
  • Bayer
  • BC Partners
  • Becton and Dickinson (BD)
  • Beijing Double-Crane Pharmaceutical
  • Bentley
  • Biocraft
  • Biogal
  • Bionomics
  • Biotest
  • BioWa
  • Boehringer Ingelheim
  • Bridgepoint Capital
  • Bristol-Myers Squibb (BMS)
  • Britest
  • Canyon
  • Carbogen Amcis
  • Cardinal Health
  • Catalent
  • Celladon
  • Celldex Therapeutics
  • Celsion
  • CEVEC Pharmaceuticals
  • Chemtrix BV
  • China National Pharmaceutical Group (SInopharm)
  • Chirotech
  • Circadian Technologies
  • Cleveland BioLabs
  • Cobra Biomanufacturing
  • Companies House
  • CordenPharma
  • Corvette Pharmaceutical Services
  • Daiichi Sankyo
  • Daito
  • DecImmune Therapeutics
  • Delmas Perfusion
  • Delpharm
  • Divis Laboratories
  • DPx Holdings
  • Dr. Reddy's Laboratories
  • Dragenopharm Apotheker Püschl and Swiss Caps
  • Eclipse Therapeutics
  • Eisai
  • Eli Lilly
  • EmulTech
  • Esteve Química
  • Euro Vital Pharma
  • Euticals
  • Evonik Degussa
  • Excella
  • Exelixis
  • Famar
  • Fareva
  • Farmaprojects
  • Frazier Healthcare
  • Fuyang Xinghai Investment
  • Genentech
  • Genzyme
  • GSK
  • Corixa
  • Haupt Pharma
  • Health Canada
  • Hejiang Jiang Yuan Tang Biotechnology
  • Human Genome Sciences
  • ICI
  • Immune Pharmaceuticals
  • Immunomedics
  • Index Ventures
  • Indoco Remedies
  • Intellect Neurosciences
  • International Chemical Investors Group
  • Ivax API
  • JK Pharmaceutical
  • JLL Partners
  • Johnson & Johnson (J&J)
  • Kadmon
  • Laboratoires Besins
  • Lanxess Corporation
  • LBO Italia Investimenti s.r.l
  • Lonza
  • Marinopoulos Group.
  • MedImmune
  • Merck KGaA
  • Merck Serono
  • Mesoblast
  • Molecular Partners
  • Moody's Corporation
  • Mylan
  • Nipro Corporation
  • Novartis
  • Novasep
  • Novozymes
  • NPS
  • OctoPlus
  • OncoMed Pharmaceuticals
  • Opthea
  • Osiris Therapeutics
  • Otsuka Pharmaceutical
  • Pantec
  • Patheon
  • Perrigo
  • PFC
  • Pfizer
  • Pharmacia
  • Pharmacyclis
  • Pharmintraco
  • Piramal
  • Plantex
  • Poli Industria Chimica
  • Progenics Pharmaceuticals
  • Prosintex
  • R5 Pharmaceuticals
  • RAG AG
  • Ranbaxy Labs
  • Recipharm
  • Regeneus
  • Relthy Laboratórios
  • Relypsa
  • Respirics
  • Rexim
  • Roche
  • Royal DSM
  • Sandoz
  • Sanofi
  • Sanwa Kagaku Kenkyusho
  • Schering
  • ScinoPharm
  • Seattle Genetics
  • Sentry BioPharma Services
  • Servier
  • Shandong Tianda Biological Pharmaceutica
  • Shandong Xinhua Pharmaceutical
  • Shanghai Pharmaceutical
  • ShangPharma
  • Shire
  • Sicor
  • Siegfried
  • Sigmar Italia
  • Silverfleet Capital
  • Sinochem
  • SkyePharma
  • Solvay
  • Sun Pharma
  • Supernus Pharmaceuticals
  • SurModics
  • Swedbank
  • Swedish Orphan Biovitrium AB (Sobi)
  • Synkem
  • Syntex
  • Synthon
  • Takeda
  • Temmler Group
  • Tessenderlo Group
  • Teva Pharmaceutical Industries
  • Theramax
  • Tianjin Tianyo Pharmaceuticals
  • Tianma Tianji
  • Tunitas Therapeutics
  • UCB
  • UMN Pharma
  • UniQure
  • Vetter Pharma
  • Vidara
  • ViroPharma
  • Vivante GMP Solutions
  • VTU Technology
  • West Pharma
  • Wockhardt
  • XOMA
  • Yiwu Huayi Investment
  • Zhangjiang Biotech & Pharmaceutical Base Company
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals

Organizations Mentioned in the Report:

  • Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Eindhoven University of Technology
  • European Medicines Agency (EMA)
  • Générique Même Médicament (GEMME)
  • Japanese Ministry of Health Labor and Welfare (MHWL)
  • Japanese Pharmaceutical and Medical Devices Agency (PMDA)
  • NIH CRM
  • Sanquin Blood Supply Foundation
  • UK Health and Safety Executive
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • University College London (UCL)
  • University of Bradford
  • University of Durham
  • University of Leeds
  • US Food and Drug Administration (FDsA)
Back to Top